Physician profile
Aaron Kolar
NPI 1154958148
$1,169.41
in general payments reported to CMS, 2019-2025
17 companies · $433 in 2025
The $433 reported for 2025 was more than what 82% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $158 · 2024: $578 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $308.43 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $125.22 | 2024-2025 | Farxiga |
| Pfizer INC. | $102.49 | 2023-2025 | |
| Lilly USA, LLC | $89.07 | 2024-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $86.02 | 2023-2024 | Arexvy, Bexsero, Shingrix |
| Abbvie INC. | $82.76 | 2024-2025 | |
| Corium, LLC | $80.79 | 2023-2024 | Azstarys |
| Exact Sciences Corporation | $73.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Tris Pharma INC | $46.89 | 2023-2024 | Dyanavel Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.95 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $27.75 | 2025 | Voquezna |
| Tactile Systems Technology INC | $26.93 | 2025 | Flexitouch Plus, Nimbl |
| Beta Bionics, INC. | $20.31 | 2024 | Ilet Bionic Pancreas |
| Dexcom, INC. | $19.17 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $15.60 | 2025 | Vaxneuvance, Proquad, Capvaxive |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $15.57 | 2024 | Trintellix |
| Cipher Pharmaceuticals US LLC | $15.10 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Kolar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.